There is initial evidence that neuroinflammation may precede abnormal protein aggregation and brain atrophy in pre-symptomatic carriers of MAPT mutations (Bevan-Jones et al., 2019), although further studies are needed to confirm these preliminary findings in AD or other neurodegenerative diseases. This evidence concerns the gene MAPT and neurodegenerative disease.